A waste record can account for the volume without confirming what is in the liquid. Waste testing helps answer a different question: does the discarded sample match the expected medication?
ASHP: include random assays in surveillance
ASHP’s 2022 guidelines recommend identifying high-risk controlled substances for random assays and including waste from all high-risk or high-volume areas in random testing procedures. Examples include sterile preparation, surgery, and anesthesia areas.1
The guidelines also address maintaining chain of custody when samples move to pharmacy. For controlled-substance waste from compounded sterile preparations within pharmacy, they specify a cosignature and random assays at least quarterly.1
ISMP: consider testing injectable waste
In its March 2023 diversion recommendations, ISMP advises considering pharmacy testing of randomly selected injectable waste, using a refractometer or another technology, to check whether the sample contains the expected medication.2
ISMP also calls for attentive witnessing, checking the label and amount against the physical product, and reconciling dispensed, administered, and wasted quantities in high-risk settings.2
Make the evidence useful to your team
Make waste testing a defined part of your program, with a clear path from collection to review. Start with:
- Coverage: which medications, concentrations, and care areas your testing approach can support.
- Workflow: where testing happens and how the sample stays connected to its event record.
- Follow-up: who reviews unexpected findings and what supporting information they need.
Testing methods differ. Your evaluation should include their supported ranges, limitations, and ability to distinguish the substances relevant to your formulary.
Where WasteWitness fits
WasteWitness adds chemical evidence of drug identity and concentration, plus separately measured volume. Teams review these findings alongside documentation to identify discrepancies and guide follow-up.
Explore supported medications and concentrations and discuss a testing workflow that fits your health system or hospital.
These publications support waste testing within a broader diversion program. They do not endorse WasteWitness or establish a universal requirement to chemically test every waste event. Product selection and implementation remain the hospital’s responsibility.
Read the original sources
- ASHP Guidelines on Preventing Diversion of Controlled Substances
Clark J, et al. American Journal of Health-System Pharmacy. 2022;79:2279 - 2306. See Monitoring and surveillance, p. 2287; Returns, waste, and disposal, pp. 2291 - 2292.
Read the ASHP guidelines (PDF) (opens in a new tab) - Controlled substance drug diversion by healthcare workers as a threat to patient safety - Part II
Institute for Safe Medication Practices. Medication Safety Alert! Acute Care. March 9, 2023;28(5). See Returns, Waste, and Disposal, p. 3; Identify, p. 4.
Read the ISMP article (PDF) (opens in a new tab)
